The Centers for Medicare & Medicaid Services (CMS) has proposed a major update to Medicare coverage for Transcatheter Aortic Valve Replacement (TAVR). The proposal aims to expand access to the minimally invasive heart procedure and allow more patients to receive treatment earlier in the course of disease.
If finalized, the new policy could reshape care for patients with severe aortic stenosis. In addition, it could strengthen the position of leading device manufacturers and accelerate the adoption of TAVR across the United States.
Understanding TAVR and Aortic Stenosis
Transcatheter Aortic Valve Replacement, commonly known as TAVR, is a minimally invasive procedure used to replace a narrowed aortic valve. The condition, called severe aortic stenosis, restricts blood flow from the heart and can lead to serious complications if left untreated.
Unlike open-heart surgery, TAVR uses a catheter to implant an artificial valve. As a result, patients often experience shorter hospital stays and faster recovery times. Over the last decade, the procedure has become a preferred option for many older adults and high-risk patients.
Why CMS Is Expanding Coverage
CMS believes the growing body of clinical evidence supports broader access to TAVR. Therefore, the agency has proposed significant changes to its National Coverage Determination (NCD).
Coverage for Asymptomatic Patients
One of the biggest updates is the proposed Medicare coverage for patients with asymptomatic severe aortic stenosis. Currently, Medicare mainly covers patients who already show symptoms.
Under the proposal, asymptomatic patients could receive TAVR if they participate in a CMS-approved clinical study. This change reflects recent evidence showing that earlier intervention may improve patient outcomes and reduce complications.
The policy follows the FDA’s expanded approval of Edwards Lifesciences’ Sapien 3 valve for asymptomatic patients in 2025. The approval was based on the EARLY TAVR trial, which demonstrated better outcomes for patients treated early rather than waiting for symptoms to appear.
Removal of Evidence Development Requirements
CMS also proposes ending the Coverage with Evidence Development (CED) requirement for symptomatic severe aortic stenosis patients.
Previously, providers had to meet additional evidence-generation requirements to receive Medicare reimbursement. The new proposal would remove that burden and simplify access to care. Furthermore, CMS plans to revise hospital and physician eligibility requirements while maintaining quality standards.
Benefits for Patients and Providers
The proposed policy could provide several important benefits.
Earlier Treatment
Patients may receive treatment before symptoms worsen. Consequently, doctors could intervene sooner and potentially improve long-term outcomes.
Improved Access
By easing procedural requirements and removing CED obligations for symptomatic patients, CMS may allow more hospitals and physicians to offer TAVR services. This change could increase access, especially in underserved areas.
Simplified Care Pathways
Healthcare providers may spend less time navigating administrative hurdles. Therefore, they can focus more on patient care and clinical outcomes.
Impact on Medical Device Companies
The proposed expansion could significantly affect the competitive landscape of the medical device industry.
Edwards Lifesciences May Benefit Most
Industry analysts believe the policy may help Edwards Lifesciences expand its market share. The company already dominates the TAVR market, and the broader Medicare coverage could accelerate adoption of its Sapien valve platform.
TAVR remains Edwards’ largest business segment. In fact, it generated nearly 74% of the company’s revenue at the end of 2025 and produced approximately $4.5 billion in annual sales.
Competition Could Intensify
At the same time, competitors such as Medtronic and Boston Scientific will likely seek to strengthen their offerings. As Medicare expands access, the TAVR market could become increasingly competitive and innovative.
What Happens Next?
CMS has opened a 30-day public comment period for stakeholders, physicians, healthcare organizations, and industry leaders.
After reviewing public feedback, the agency plans to issue a final decision memo in September 2026. If approved, the policy could mark one of the most significant Medicare coverage updates for cardiovascular care in recent years.
Future of TAVR Under Medicare
The CMS proposal signals a broader shift toward earlier intervention and evidence-based cardiovascular care.
By expanding coverage to asymptomatic patients and reducing administrative barriers, CMS aims to improve outcomes while preserving patient safety. Moreover, the changes could encourage innovation across the medical device industry and make advanced heart therapies more accessible to millions of Medicare beneficiaries.
As the public comment period unfolds, healthcare providers, patients, and manufacturers will closely watch the agency’s final decision. If finalized, the proposal could usher in a new era of TAVR adoption and redefine the standard of care for severe aortic stenosis in the United States.
